<DOC>
	<DOC>NCT00939731</DOC>
	<brief_summary>The study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over, single-dose study employing administration of two PF-02341066 formulations in the fasted state to healthy adult volunteers.</brief_summary>
	<brief_title>Relative Drug Exposures Of Two Formulations of PF-02341066</brief_title>
	<detailed_description />
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Healthy male and/or female of nonchildbearing potential subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12lead electrocardiogram(ECG) and clinical laboratory tests). Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 halflives preceding the first dose of study medication. Pregnant or nursing females; females of childbearing potential, including those with tubal ligation. To be considered for enrollment, women of 45 to 55 years of age who are postmenopausal (defined as being amenorrheic for at least 2 years) must have confirmatory Folliclestimulating hormone(FSH) test results at Screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>bioavailability, capsule, tablet, healthy volunteer</keyword>
</DOC>